Search results for: 'Lung Cancer Therapeutics Market Siz'

15 May 2025  |  Global  |  Market Research

Immunomodulator Therapeutics Market, Global, 2024–2030

Mechanism-targeted Approaches are Driving Transformational Growth by Enabling Innovation in Autoimmune, Oncology, and Inflammatory Therapies

Infographics

×

This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting...

This study explores the transformative potential of organoid technologies in advancing cancer research, precision medicine, and drug discovery. Organoids—3D cell culture systems derived from patient tumors—preserve tumor heterogeneity and provide physiologically relevant models for studying cancer biology, therapeutic response, and resistance mecha...

Emerging Therapeutics in the U.S. Colorectal Cancer Market is a rapidly progressing field that is set to generate over $2 billion in revenue in the coming years. The market has witnessed unprecedented growth with the launch of a new segment and as a result competition has increased in the cytotoxic market. The dynamics of this market are changing...

Digital therapeutics are about to become a true medical alternative that will utilize communications-based technologies, apps, and software to improve patient outcomes and help to lower the cost of healthcare. The overall digital therapeutics market is expected to grow at a compound annual growth rate of 30.7% from 2017 to 2023. This report emp...

21 Sep 2023  |  North America  |  Market Research

Growth Opportunities in the Global Digital Therapeutics Market

Preventive Care and Market Access Strategies Spur New Growth Opportunities

Infographics

×

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global digital therapeutics (DTx) market and highlights key growth opportunities for global DTx market participants. Patients with long-term chronic conditions increasingly seek safe, evidence-based digital treatments to reduce their medication dosages,...

15 to 20 million new cases of cancer are diagnosed every year. Radiotherapy is the gold standard for treatment and is used on more than 3.5 million people and provided as palliative or adjunct treatment for an additional 3.5 million people, worldwide. Nearly 50 percent of all cancer patients are estimated to benefit from radiotherapy for disease ma...

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms—including in vivo CRISPR gene editing, allogeneic “off-the-shelf” cell therapies, and automated sm...

RNA therapeutics is a rapidly expanding field of next-generation medicine. RNA therapy typically comprises 4 different classes of molecules: non-codingRNA (ncRNA), antisense oligonucleotide (ASO), messengerRNA (mRNA), and RNA aptamer. Small ncRNAs are like a double-edged sword; they can either up- or down-regulate specific genes. Contrarily, long...

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...